Patients with Atopic Dermatitis Colonized with Staphylococcus aureus Have a Distinct Phenotype and Endotype

Eric Simpson, Miguel Villarreal, Brett Jepson, Nick Rafaels, Gloria David, Jon Hanifin, Patricia Taylor, Mark Boguniewicz, Takeshi Yoshida, Anna De Benedetto, Kathleen C. Barnes, Donald Y.M. Leung, Lisa A. Beck

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Patients with atopic dermatitis (AD) are commonly colonized with Staphylococcus aureus (AD S. aureus+), but what differentiates this group from noncolonized AD patients (AD S. aureus) has not been well studied. To evaluate whether these two groups have unique phenotypic or endotypic features, we performed a multicenter, cross-sectional study enrolling AD S. aureus+ (n = 51) and AD S. aureus (n = 45) participants defined by the presence or absence of S. aureus by routine culture techniques and nonatopic, noncolonized control individuals (NA S. aureus) (n = 46). Filaggrin (FLG) genotypes were determined, and disease severity (Eczema Area and Severity Index, Rajka-Langeland Severity Score, Investigator's Global Assessment score, Numerical Rating Scale, and Dermatology Life Quality Index) was captured. Skin physiology was assessed (transepidermal water loss [TEWL], stratum corneum integrity, hydration, and pH), and serum biomarkers were also measured. We found that AD S. aureus+ patients had more severe disease based on all scoring systems except itch (Numerical Rating Scale), and they had higher levels of type 2 biomarkers (eosinophil count, tIgE, CCL17, and periostin). Additionally, AD S. aureus+ patients had significantly greater allergen sensitization (Phadiatop and tIgE), barrier dysfunction (TEWL and stratum corneum integrity), and serum lactate dehydrogenase (LDH) than both the AD S. aureus and NA S. aureus groups. FLG mutations did not associate with S. aureus+ colonization. In conclusion, adult patients with AD who are colonized on their skin with S. aureus have more severe disease, greater type 2 immune deviation, allergen sensitization, barrier disruption, and LDH level elevation than noncolonized patients with AD.

Original languageEnglish (US)
JournalJournal of Investigative Dermatology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Atopic Dermatitis
Staphylococcus aureus
Phenotype
Biomarkers
L-Lactate Dehydrogenase
Allergens
Skin
Cornea
Dermatology
Skin Physiological Phenomena
Water
Physiology
Culture Techniques
Hydration
Eczema
Serum
Eosinophils
Cross-Sectional Studies
Genotype
Quality of Life

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Dermatology
  • Cell Biology

Cite this

Patients with Atopic Dermatitis Colonized with Staphylococcus aureus Have a Distinct Phenotype and Endotype. / Simpson, Eric; Villarreal, Miguel; Jepson, Brett; Rafaels, Nick; David, Gloria; Hanifin, Jon; Taylor, Patricia; Boguniewicz, Mark; Yoshida, Takeshi; De Benedetto, Anna; Barnes, Kathleen C.; Leung, Donald Y.M.; Beck, Lisa A.

In: Journal of Investigative Dermatology, 01.01.2018.

Research output: Contribution to journalArticle

Simpson, E, Villarreal, M, Jepson, B, Rafaels, N, David, G, Hanifin, J, Taylor, P, Boguniewicz, M, Yoshida, T, De Benedetto, A, Barnes, KC, Leung, DYM & Beck, LA 2018, 'Patients with Atopic Dermatitis Colonized with Staphylococcus aureus Have a Distinct Phenotype and Endotype', Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2018.03.1517
Simpson, Eric ; Villarreal, Miguel ; Jepson, Brett ; Rafaels, Nick ; David, Gloria ; Hanifin, Jon ; Taylor, Patricia ; Boguniewicz, Mark ; Yoshida, Takeshi ; De Benedetto, Anna ; Barnes, Kathleen C. ; Leung, Donald Y.M. ; Beck, Lisa A. / Patients with Atopic Dermatitis Colonized with Staphylococcus aureus Have a Distinct Phenotype and Endotype. In: Journal of Investigative Dermatology. 2018.
@article{ff05d34ed1934047bc9e48a8b17d6d42,
title = "Patients with Atopic Dermatitis Colonized with Staphylococcus aureus Have a Distinct Phenotype and Endotype",
abstract = "Patients with atopic dermatitis (AD) are commonly colonized with Staphylococcus aureus (AD S. aureus+), but what differentiates this group from noncolonized AD patients (AD S. aureus–) has not been well studied. To evaluate whether these two groups have unique phenotypic or endotypic features, we performed a multicenter, cross-sectional study enrolling AD S. aureus+ (n = 51) and AD S. aureus– (n = 45) participants defined by the presence or absence of S. aureus by routine culture techniques and nonatopic, noncolonized control individuals (NA S. aureus–) (n = 46). Filaggrin (FLG) genotypes were determined, and disease severity (Eczema Area and Severity Index, Rajka-Langeland Severity Score, Investigator's Global Assessment score, Numerical Rating Scale, and Dermatology Life Quality Index) was captured. Skin physiology was assessed (transepidermal water loss [TEWL], stratum corneum integrity, hydration, and pH), and serum biomarkers were also measured. We found that AD S. aureus+ patients had more severe disease based on all scoring systems except itch (Numerical Rating Scale), and they had higher levels of type 2 biomarkers (eosinophil count, tIgE, CCL17, and periostin). Additionally, AD S. aureus+ patients had significantly greater allergen sensitization (Phadiatop and tIgE), barrier dysfunction (TEWL and stratum corneum integrity), and serum lactate dehydrogenase (LDH) than both the AD S. aureus– and NA S. aureus– groups. FLG mutations did not associate with S. aureus+ colonization. In conclusion, adult patients with AD who are colonized on their skin with S. aureus have more severe disease, greater type 2 immune deviation, allergen sensitization, barrier disruption, and LDH level elevation than noncolonized patients with AD.",
author = "Eric Simpson and Miguel Villarreal and Brett Jepson and Nick Rafaels and Gloria David and Jon Hanifin and Patricia Taylor and Mark Boguniewicz and Takeshi Yoshida and {De Benedetto}, Anna and Barnes, {Kathleen C.} and Leung, {Donald Y.M.} and Beck, {Lisa A.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.jid.2018.03.1517",
language = "English (US)",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Patients with Atopic Dermatitis Colonized with Staphylococcus aureus Have a Distinct Phenotype and Endotype

AU - Simpson, Eric

AU - Villarreal, Miguel

AU - Jepson, Brett

AU - Rafaels, Nick

AU - David, Gloria

AU - Hanifin, Jon

AU - Taylor, Patricia

AU - Boguniewicz, Mark

AU - Yoshida, Takeshi

AU - De Benedetto, Anna

AU - Barnes, Kathleen C.

AU - Leung, Donald Y.M.

AU - Beck, Lisa A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Patients with atopic dermatitis (AD) are commonly colonized with Staphylococcus aureus (AD S. aureus+), but what differentiates this group from noncolonized AD patients (AD S. aureus–) has not been well studied. To evaluate whether these two groups have unique phenotypic or endotypic features, we performed a multicenter, cross-sectional study enrolling AD S. aureus+ (n = 51) and AD S. aureus– (n = 45) participants defined by the presence or absence of S. aureus by routine culture techniques and nonatopic, noncolonized control individuals (NA S. aureus–) (n = 46). Filaggrin (FLG) genotypes were determined, and disease severity (Eczema Area and Severity Index, Rajka-Langeland Severity Score, Investigator's Global Assessment score, Numerical Rating Scale, and Dermatology Life Quality Index) was captured. Skin physiology was assessed (transepidermal water loss [TEWL], stratum corneum integrity, hydration, and pH), and serum biomarkers were also measured. We found that AD S. aureus+ patients had more severe disease based on all scoring systems except itch (Numerical Rating Scale), and they had higher levels of type 2 biomarkers (eosinophil count, tIgE, CCL17, and periostin). Additionally, AD S. aureus+ patients had significantly greater allergen sensitization (Phadiatop and tIgE), barrier dysfunction (TEWL and stratum corneum integrity), and serum lactate dehydrogenase (LDH) than both the AD S. aureus– and NA S. aureus– groups. FLG mutations did not associate with S. aureus+ colonization. In conclusion, adult patients with AD who are colonized on their skin with S. aureus have more severe disease, greater type 2 immune deviation, allergen sensitization, barrier disruption, and LDH level elevation than noncolonized patients with AD.

AB - Patients with atopic dermatitis (AD) are commonly colonized with Staphylococcus aureus (AD S. aureus+), but what differentiates this group from noncolonized AD patients (AD S. aureus–) has not been well studied. To evaluate whether these two groups have unique phenotypic or endotypic features, we performed a multicenter, cross-sectional study enrolling AD S. aureus+ (n = 51) and AD S. aureus– (n = 45) participants defined by the presence or absence of S. aureus by routine culture techniques and nonatopic, noncolonized control individuals (NA S. aureus–) (n = 46). Filaggrin (FLG) genotypes were determined, and disease severity (Eczema Area and Severity Index, Rajka-Langeland Severity Score, Investigator's Global Assessment score, Numerical Rating Scale, and Dermatology Life Quality Index) was captured. Skin physiology was assessed (transepidermal water loss [TEWL], stratum corneum integrity, hydration, and pH), and serum biomarkers were also measured. We found that AD S. aureus+ patients had more severe disease based on all scoring systems except itch (Numerical Rating Scale), and they had higher levels of type 2 biomarkers (eosinophil count, tIgE, CCL17, and periostin). Additionally, AD S. aureus+ patients had significantly greater allergen sensitization (Phadiatop and tIgE), barrier dysfunction (TEWL and stratum corneum integrity), and serum lactate dehydrogenase (LDH) than both the AD S. aureus– and NA S. aureus– groups. FLG mutations did not associate with S. aureus+ colonization. In conclusion, adult patients with AD who are colonized on their skin with S. aureus have more severe disease, greater type 2 immune deviation, allergen sensitization, barrier disruption, and LDH level elevation than noncolonized patients with AD.

UR - http://www.scopus.com/inward/record.url?scp=85047400674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047400674&partnerID=8YFLogxK

U2 - 10.1016/j.jid.2018.03.1517

DO - 10.1016/j.jid.2018.03.1517

M3 - Article

C2 - 29604251

AN - SCOPUS:85047400674

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

ER -